Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Healthcare - stethoscope-with-injection-protective-mask-lying-over-medical-chart-SBI-300904603
5 Biotech Stocks With 26% Upside Potential or More Barchart - Thu Mar 7, 1:13PM CST

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

$SPX : 5,116.17 (+0.32%)
NVO : 126.88 (+0.02%)
BIIB : 215.50 (+3.16%)
KNSA : 18.55 (+3.75%)
SWTX : 46.45 (+2.02%)
RLAY : 6.59 (+3.45%)
ADPT : 2.75 (+5.77%)
GS : 430.81 (+0.76%)
SpringWorks Therapeutics: Q4 Earnings Snapshot AP - Tue Feb 27, 5:44AM CST

SpringWorks Therapeutics: Q4 Earnings Snapshot

SWTX : 46.45 (+2.02%)
SpringWorks Therapeutics: Q3 Earnings Snapshot AP - Thu Nov 2, 2023

SpringWorks Therapeutics: Q3 Earnings Snapshot

SWTX : 46.45 (+2.02%)
SpringWorks Therapeutics: Q2 Earnings Snapshot AP - Wed Aug 2, 2023

SpringWorks Therapeutics: Q2 Earnings Snapshot

SWTX : 46.45 (+2.02%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 FinancialNewsMedia - Thu Jun 1, 2023

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 6.92 (-4.42%)
DAWN : 16.48 (+10.46%)
SWTX : 46.45 (+2.02%)
VSTM : 9.63 (+2.67%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 6.92 (-4.42%)
SWTX : 46.45 (+2.02%)
DAWN : 16.48 (+10.46%)
VSTM : 9.63 (+2.67%)
KNTE : 2.65 (-0.38%)
SpringWorks Therapeutics: Q1 Earnings Snapshot AP - Wed May 3, 2023

SpringWorks Therapeutics: Q1 Earnings Snapshot

SWTX : 46.45 (+2.02%)
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 Business Wire - Mon Apr 17, 2023

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s...

BGNE : 156.53 (+1.92%)
SWTX : 46.45 (+2.02%)
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023 Business Wire - Mon Apr 17, 2023

MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b...

BGNE : 156.53 (+1.92%)
SWTX : 46.45 (+2.02%)
SpringWorks Therapeutics: Q4 Earnings Snapshot AP - Tue Feb 28, 2023

SpringWorks Therapeutics: Q4 Earnings Snapshot

SWTX : 46.45 (+2.02%)

Barchart Exclusives

Here's Why Novo Nordisk Stock Is a Buy Right Now Barchart - 35 minutes ago
Novo Nordisk stock has surged, outperforming the market this year. Here's why it still looks like a buy right now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot